Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

GLG News by Multiple Myeloma Physicians

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Omapro will fill a CML void

November 14, 2009

US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com

Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC) What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

What is potential future for Sequenom in prenatal testing.

November 9, 2009

So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com

The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably, this article asserts that industry insiders remain optimistic about the development of a successful diagnostic product.

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC) What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Potential impact of large clinical trial on Liquid based cytology market

November 5, 2009

Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com

The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there is evidence that would reverse this. However, it is possible such studies will put downward pricing pressures on reimbursments, both in amounts and frequencies.

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Triple negative Breast Cancer Strategies

October 14, 2009

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC) What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

New entrant to DTC genetic testing market raises regulatory and financial questions

July 16, 2009

New DTC Genetics Firm Pathway Genomics Launches | www.genomeweb.com

Pathway Genomics is the latest entrant into the DTC genetic testing market.   They offer an extensive amount of genetic information (over 90 individual results) at a price point of $250.  This undercuts both existing DTC providers, like 23andme, decode genetics, etc., but also appropriately licensed genetics providers.        These companies seem to be threading the needle between providing a service for "research and education only", with extensive legal disclamers, and providing useful information and interpretations which affect medical decisions.  Sooner or later, governmental agencies have to make a decision on whether to clearly subject these companies to explicit regulatory scrutiny, both at the federal and state level.      Notwithstanding, this company would seem poised f

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC) What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Analyst upgrades of Genomic Health: Lagging or leading indicator

June 12, 2009

Analyst Upgrades Genomic Health | www.genomeweb.com

Genomic Health is a molecular diagnostic company with one major product on the market and others potentially in the pipeline.   Wall street has had only modest coverage of this company and generally assessments have been neutral.  In assessing this company, it is important to recognize that it has some unique positive features in its business model, as well as some downside risks of potentially great magnitude. 

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Pay for performance Medicare "reform"

May 4, 2009

Medicare System Overhaul Proposed by Two Senators | www.nytimes.com

Medicare will reward based on outcome Medicare will pay for chronic illness acre based on outcome results Be careful about heading towards cancer care rationing

Page : 12345678910Next1 to 10 of 237

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News